Immune Pharmaceuticals to price public offering of common-share units

Proceeds fund general corporate purposes, including clinical trials

By Devika Patel

Knoxville, Tenn., Nov. 19 – Immune Pharmaceuticals Inc. will price a public offering of units with a 30-day greenshoe option, according to a preliminary prospectus supplement filed Wednesday with the Securities and Exchange Commission.

The company will sell units of common shares and warrants.

National Securities Corp. is the bookrunner.

Proceeds will be used for general corporate purposes, including research and development, clinical trials, acquisitions, capital expenditures and working capital.

The specialty pharmaceutical company is based in Tarrytown, N.Y.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.